Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.33 |
| ▸ | CDK2 | P24941 | 7/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18840022 | 0.98 | L3MBTL1 (0.36) | L3MBTL1EPHX1DPP4CHRNB2CHRNA4 | |
| Acetic Acid SCHEMBL27620806 | 0.94 | L3MBTL1 (0.34) | L3MBTL1EPHX1DPP4CHRNB2CHRNA4 | |
| SCHEMBL20502636 | 0.86 | DPP4 (0.33) | L3MBTL1DPP4CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1441784 | 0.85 | CHRM3 (0.35) | L3MBTL1DPP4SSTR4CCNE1CDK2 | |
| SCHEMBL954529 | 0.85 | CHRM3 (0.35) | L3MBTL1DPP4SSTR4CCNE1CDK2 | |
| SCHEMBL954528 | 0.85 | CHRM3 (0.35) | L3MBTL1DPP4SSTR4CCNE1CDK2 | |
| Hydrochloric Acid SCHEMBL28057619 | 0.84 | DPP4 (0.35) | L3MBTL1DPP4SSTR4CCNE1CDK2 | |
| Methane SCHEMBL27926432 | 0.84 | CHRM3 (0.34) | L3MBTL1DPP4SSTR4CCNE1CDK2 | |
| SCHEMBL740082 | 0.83 | SLC6A1 (0.37) | L3MBTL1EPHX1DPP4SSTR4CCNE1 | |
| Bicarbonate SCHEMBL1532914 | 0.83 | CHRM3 (0.36) | L3MBTL1DPP4CCNE1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225756-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| CN-111662232-B | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2022-08-02 | — | — | CN | disclosed |
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| CN-106573915-B | Compounds active against bromodomains | 纽韦卢森公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-111662232-A | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-09-15 | — | — | CN | disclosed |
| EP-1829879-A1 | Amino pyrimidine compounds for the treatment of inflammatory disorders | Cellzome (UK) Ltd. (GB) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007090854-A1 | AZETIDINE AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090852-A1 | AMINO PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
| CN-1901916-A | Quinazolinone compounds with reduced in vivo accumulation | CHIRON CORP (US) | 2007-01-24 | — | — | CN | disclosed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| CN-1829517-A | Guanidino-substituted quinazolines as MC 4-R agonists | CHIRON CORP (US) | 2006-09-06 | — | — | CN | disclosed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
| CN-1636990-A | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LAB (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1192028-C | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2005-03-09 | — | — | CN | disclosed |
| CN-1361774-A | Heterocyclic substituted amino nitrogen heterocycles as central nervous system medicaments | ABBOTT INC (US) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889591-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | L3MBTL1 3651/4885EPHX1 427/4885DPP4 99/4885 |
| US-20210130366-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | L3MBTL1 3651/4885EPHX1 427/4885DPP4 99/4885 |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | TFPI, TFPI2, F11 | L3MBTL1 4750/4885EPHX1 1862/4885DPP4 1130/4885 |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | L3MBTL1 4750/4885EPHX1 1862/4885DPP4 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.